世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

経口TYK2阻害剤の世界市場成長(現状と展望)2024-2030年


Global Oral TYK2 Inhibitor Market Growth (Status and Outlook) 2024-2030

世界の経口TYK2阻害剤市場規模は、2023年の100万米ドルから2030年には100万米ドルに成長すると予測され、2024年から2030年までの年平均成長率は%と予測されています。 LPI(エルピーアイ情報)の最新調査レポー... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年4月16日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
93 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

世界の経口TYK2阻害剤市場規模は、2023年の100万米ドルから2030年には100万米ドルに成長すると予測され、2024年から2030年までの年平均成長率は%と予測されています。
LPI(エルピーアイ情報)の最新調査レポート「経口TYK2阻害剤産業予測」は、2023年の経口TYK2阻害剤の過去の売上高と世界全体の売上高を調査し、2024年から2030年までの経口TYK2阻害剤の売上高予測について地域別・市場分野別に包括的に分析しています。経口TYK2インヒビターの売上高を地域別、市場分野別、サブセクター別に分類し、世界の経口TYK2インヒビター産業の詳細な分析を百万米ドル単位で提供します。
この調査レポートは、世界の経口TYK2阻害剤業界を包括的に分析し、製品区分、企業形成、収益、市場シェア、最新動向、M&A活動などに関する主要動向を明らかにしています。また本レポートでは、経口TYK2阻害剤のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、主要グローバル企業の戦略を分析し、加速する世界の経口TYK2阻害剤市場におけるこれらの企業の独自の地位をより良く理解しています。
本インサイトレポートでは、経口TYK2阻害剤の世界的な見通しを形成する主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化して、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界の経口TYK2阻害剤の現状と将来の軌道について非常にニュアンスのある見解を提供します。
経口TYK2阻害剤の米国市場は、2023年の100万米ドルから2030年までに100万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。
経口TYK2阻害剤の中国市場は、2023年の百万米ドルから2030年には百万米ドルに、2024年から2030年までの年平均成長率は%と推定される。
経口TYK2阻害剤のヨーロッパ市場は、2023年の百万米ドルから2030年には百万米ドルに、2024年から2030年までの年平均成長率は%と推定される。
経口TYK2阻害剤の世界的な主要企業は、Bristol-Myers Squibb、InnoCare Pharma、武田薬品(Nimbus Therapeutics)、E-nitiate Biopharmaceuticals、Highlightll Pharmaceuticalsなどである。売上高では、世界の大手2社が2023年にほぼ%のシェアを占めています。
この調査レポートは、経口TYK2阻害剤市場の製品タイプ、用途、主要企業、主要地域、国別の包括的な概要、市場シェア、成長機会を掲載しています。
タイプ別セグメンテーション
シングルターゲット阻害剤
デュアルターゲットインヒビター
用途別セグメント
乾癬
アトピー性皮膚炎
その他
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ブリストル・マイヤーズ スクイブ
イノケアファーマ
武田薬品(ニンバス・セラピューティクス)
イー・ニチアテ・バイオファーマ
Highlightll Pharmaceuticals
ファイザー
アルミス・インク
ガラパゴスNV
ヴェンティクス・バイオサイエンス


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral TYK2 Inhibitor Market Size 2019-2030
2.1.2 Oral TYK2 Inhibitor Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Oral TYK2 Inhibitor Segment by Type
2.2.1 Single-target Inhibitor
2.2.2 Dual-target Inhibitor
2.3 Oral TYK2 Inhibitor Market Size by Type
2.3.1 Oral TYK2 Inhibitor Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Oral TYK2 Inhibitor Market Size Market Share by Type (2019-2024)
2.4 Oral TYK2 Inhibitor Segment by Application
2.4.1 Psoriasis
2.4.2 Atopic Dermatitis
2.4.3 Other
2.5 Oral TYK2 Inhibitor Market Size by Application
2.5.1 Oral TYK2 Inhibitor Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Oral TYK2 Inhibitor Market Size Market Share by Application (2019-2024)
3 Oral TYK2 Inhibitor Market Size by Player
3.1 Oral TYK2 Inhibitor Market Size Market Share by Players
3.1.1 Global Oral TYK2 Inhibitor Revenue by Players (2019-2024)
3.1.2 Global Oral TYK2 Inhibitor Revenue Market Share by Players (2019-2024)
3.2 Global Oral TYK2 Inhibitor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Oral TYK2 Inhibitor by Regions
4.1 Oral TYK2 Inhibitor Market Size by Regions (2019-2024)
4.2 Americas Oral TYK2 Inhibitor Market Size Growth (2019-2024)
4.3 APAC Oral TYK2 Inhibitor Market Size Growth (2019-2024)
4.4 Europe Oral TYK2 Inhibitor Market Size Growth (2019-2024)
4.5 Middle East & Africa Oral TYK2 Inhibitor Market Size Growth (2019-2024)
5 Americas
5.1 Americas Oral TYK2 Inhibitor Market Size by Country (2019-2024)
5.2 Americas Oral TYK2 Inhibitor Market Size by Type (2019-2024)
5.3 Americas Oral TYK2 Inhibitor Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral TYK2 Inhibitor Market Size by Region (2019-2024)
6.2 APAC Oral TYK2 Inhibitor Market Size by Type (2019-2024)
6.3 APAC Oral TYK2 Inhibitor Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Oral TYK2 Inhibitor by Country (2019-2024)
7.2 Europe Oral TYK2 Inhibitor Market Size by Type (2019-2024)
7.3 Europe Oral TYK2 Inhibitor Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral TYK2 Inhibitor by Region (2019-2024)
8.2 Middle East & Africa Oral TYK2 Inhibitor Market Size by Type (2019-2024)
8.3 Middle East & Africa Oral TYK2 Inhibitor Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Oral TYK2 Inhibitor Market Forecast
10.1 Global Oral TYK2 Inhibitor Forecast by Regions (2025-2030)
10.1.1 Global Oral TYK2 Inhibitor Forecast by Regions (2025-2030)
10.1.2 Americas Oral TYK2 Inhibitor Forecast
10.1.3 APAC Oral TYK2 Inhibitor Forecast
10.1.4 Europe Oral TYK2 Inhibitor Forecast
10.1.5 Middle East & Africa Oral TYK2 Inhibitor Forecast
10.2 Americas Oral TYK2 Inhibitor Forecast by Country (2025-2030)
10.2.1 United States Oral TYK2 Inhibitor Market Forecast
10.2.2 Canada Oral TYK2 Inhibitor Market Forecast
10.2.3 Mexico Oral TYK2 Inhibitor Market Forecast
10.2.4 Brazil Oral TYK2 Inhibitor Market Forecast
10.3 APAC Oral TYK2 Inhibitor Forecast by Region (2025-2030)
10.3.1 China Oral TYK2 Inhibitor Market Forecast
10.3.2 Japan Oral TYK2 Inhibitor Market Forecast
10.3.3 Korea Oral TYK2 Inhibitor Market Forecast
10.3.4 Southeast Asia Oral TYK2 Inhibitor Market Forecast
10.3.5 India Oral TYK2 Inhibitor Market Forecast
10.3.6 Australia Oral TYK2 Inhibitor Market Forecast
10.4 Europe Oral TYK2 Inhibitor Forecast by Country (2025-2030)
10.4.1 Germany Oral TYK2 Inhibitor Market Forecast
10.4.2 France Oral TYK2 Inhibitor Market Forecast
10.4.3 UK Oral TYK2 Inhibitor Market Forecast
10.4.4 Italy Oral TYK2 Inhibitor Market Forecast
10.4.5 Russia Oral TYK2 Inhibitor Market Forecast
10.5 Middle East & Africa Oral TYK2 Inhibitor Forecast by Region (2025-2030)
10.5.1 Egypt Oral TYK2 Inhibitor Market Forecast
10.5.2 South Africa Oral TYK2 Inhibitor Market Forecast
10.5.3 Israel Oral TYK2 Inhibitor Market Forecast
10.5.4 Turkey Oral TYK2 Inhibitor Market Forecast
10.5.5 GCC Countries Oral TYK2 Inhibitor Market Forecast
10.6 Global Oral TYK2 Inhibitor Forecast by Type (2025-2030)
10.7 Global Oral TYK2 Inhibitor Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Oral TYK2 Inhibitor Product Offered
11.1.3 Bristol-Myers Squibb Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bristol-Myers Squibb Main Business Overview
11.1.5 Bristol-Myers Squibb Latest Developments
11.2 InnoCare Pharma
11.2.1 InnoCare Pharma Company Information
11.2.2 InnoCare Pharma Oral TYK2 Inhibitor Product Offered
11.2.3 InnoCare Pharma Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 InnoCare Pharma Main Business Overview
11.2.5 InnoCare Pharma Latest Developments
11.3 Takeda (Nimbus Therapeutics)
11.3.1 Takeda (Nimbus Therapeutics) Company Information
11.3.2 Takeda (Nimbus Therapeutics) Oral TYK2 Inhibitor Product Offered
11.3.3 Takeda (Nimbus Therapeutics) Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Takeda (Nimbus Therapeutics) Main Business Overview
11.3.5 Takeda (Nimbus Therapeutics) Latest Developments
11.4 E-nitiate Biopharmaceuticals
11.4.1 E-nitiate Biopharmaceuticals Company Information
11.4.2 E-nitiate Biopharmaceuticals Oral TYK2 Inhibitor Product Offered
11.4.3 E-nitiate Biopharmaceuticals Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 E-nitiate Biopharmaceuticals Main Business Overview
11.4.5 E-nitiate Biopharmaceuticals Latest Developments
11.5 Highlightll Pharmaceutical
11.5.1 Highlightll Pharmaceutical Company Information
11.5.2 Highlightll Pharmaceutical Oral TYK2 Inhibitor Product Offered
11.5.3 Highlightll Pharmaceutical Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Highlightll Pharmaceutical Main Business Overview
11.5.5 Highlightll Pharmaceutical Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Oral TYK2 Inhibitor Product Offered
11.6.3 Pfizer Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Alumis Inc.
11.7.1 Alumis Inc. Company Information
11.7.2 Alumis Inc. Oral TYK2 Inhibitor Product Offered
11.7.3 Alumis Inc. Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Alumis Inc. Main Business Overview
11.7.5 Alumis Inc. Latest Developments
11.8 Galapagos NV
11.8.1 Galapagos NV Company Information
11.8.2 Galapagos NV Oral TYK2 Inhibitor Product Offered
11.8.3 Galapagos NV Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Galapagos NV Main Business Overview
11.8.5 Galapagos NV Latest Developments
11.9 Ventyx Biosciences
11.9.1 Ventyx Biosciences Company Information
11.9.2 Ventyx Biosciences Oral TYK2 Inhibitor Product Offered
11.9.3 Ventyx Biosciences Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Ventyx Biosciences Main Business Overview
11.9.5 Ventyx Biosciences Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

The global Oral TYK2 Inhibitor market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LPI (LP Information)' newest research report, the “Oral TYK2 Inhibitor Industry Forecast” looks at past sales and reviews total world Oral TYK2 Inhibitor sales in 2023, providing a comprehensive analysis by region and market sector of projected Oral TYK2 Inhibitor sales for 2024 through 2030. With Oral TYK2 Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral TYK2 Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global Oral TYK2 Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral TYK2 Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral TYK2 Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral TYK2 Inhibitor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral TYK2 Inhibitor.
United States market for Oral TYK2 Inhibitor is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Oral TYK2 Inhibitor is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Oral TYK2 Inhibitor is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Oral TYK2 Inhibitor players cover Bristol-Myers Squibb, InnoCare Pharma, Takeda (Nimbus Therapeutics), E-nitiate Biopharmaceuticals and Highlightll Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral TYK2 Inhibitor market by product type, application, key players and key regions and countries.
Segmentation by type
Single-target Inhibitor
Dual-target Inhibitor
Segmentation by application
Psoriasis
Atopic Dermatitis
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
InnoCare Pharma
Takeda (Nimbus Therapeutics)
E-nitiate Biopharmaceuticals
Highlightll Pharmaceutical
Pfizer
Alumis Inc.
Galapagos NV
Ventyx Biosciences



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral TYK2 Inhibitor Market Size 2019-2030
2.1.2 Oral TYK2 Inhibitor Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Oral TYK2 Inhibitor Segment by Type
2.2.1 Single-target Inhibitor
2.2.2 Dual-target Inhibitor
2.3 Oral TYK2 Inhibitor Market Size by Type
2.3.1 Oral TYK2 Inhibitor Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Oral TYK2 Inhibitor Market Size Market Share by Type (2019-2024)
2.4 Oral TYK2 Inhibitor Segment by Application
2.4.1 Psoriasis
2.4.2 Atopic Dermatitis
2.4.3 Other
2.5 Oral TYK2 Inhibitor Market Size by Application
2.5.1 Oral TYK2 Inhibitor Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Oral TYK2 Inhibitor Market Size Market Share by Application (2019-2024)
3 Oral TYK2 Inhibitor Market Size by Player
3.1 Oral TYK2 Inhibitor Market Size Market Share by Players
3.1.1 Global Oral TYK2 Inhibitor Revenue by Players (2019-2024)
3.1.2 Global Oral TYK2 Inhibitor Revenue Market Share by Players (2019-2024)
3.2 Global Oral TYK2 Inhibitor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Oral TYK2 Inhibitor by Regions
4.1 Oral TYK2 Inhibitor Market Size by Regions (2019-2024)
4.2 Americas Oral TYK2 Inhibitor Market Size Growth (2019-2024)
4.3 APAC Oral TYK2 Inhibitor Market Size Growth (2019-2024)
4.4 Europe Oral TYK2 Inhibitor Market Size Growth (2019-2024)
4.5 Middle East & Africa Oral TYK2 Inhibitor Market Size Growth (2019-2024)
5 Americas
5.1 Americas Oral TYK2 Inhibitor Market Size by Country (2019-2024)
5.2 Americas Oral TYK2 Inhibitor Market Size by Type (2019-2024)
5.3 Americas Oral TYK2 Inhibitor Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral TYK2 Inhibitor Market Size by Region (2019-2024)
6.2 APAC Oral TYK2 Inhibitor Market Size by Type (2019-2024)
6.3 APAC Oral TYK2 Inhibitor Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Oral TYK2 Inhibitor by Country (2019-2024)
7.2 Europe Oral TYK2 Inhibitor Market Size by Type (2019-2024)
7.3 Europe Oral TYK2 Inhibitor Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral TYK2 Inhibitor by Region (2019-2024)
8.2 Middle East & Africa Oral TYK2 Inhibitor Market Size by Type (2019-2024)
8.3 Middle East & Africa Oral TYK2 Inhibitor Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Oral TYK2 Inhibitor Market Forecast
10.1 Global Oral TYK2 Inhibitor Forecast by Regions (2025-2030)
10.1.1 Global Oral TYK2 Inhibitor Forecast by Regions (2025-2030)
10.1.2 Americas Oral TYK2 Inhibitor Forecast
10.1.3 APAC Oral TYK2 Inhibitor Forecast
10.1.4 Europe Oral TYK2 Inhibitor Forecast
10.1.5 Middle East & Africa Oral TYK2 Inhibitor Forecast
10.2 Americas Oral TYK2 Inhibitor Forecast by Country (2025-2030)
10.2.1 United States Oral TYK2 Inhibitor Market Forecast
10.2.2 Canada Oral TYK2 Inhibitor Market Forecast
10.2.3 Mexico Oral TYK2 Inhibitor Market Forecast
10.2.4 Brazil Oral TYK2 Inhibitor Market Forecast
10.3 APAC Oral TYK2 Inhibitor Forecast by Region (2025-2030)
10.3.1 China Oral TYK2 Inhibitor Market Forecast
10.3.2 Japan Oral TYK2 Inhibitor Market Forecast
10.3.3 Korea Oral TYK2 Inhibitor Market Forecast
10.3.4 Southeast Asia Oral TYK2 Inhibitor Market Forecast
10.3.5 India Oral TYK2 Inhibitor Market Forecast
10.3.6 Australia Oral TYK2 Inhibitor Market Forecast
10.4 Europe Oral TYK2 Inhibitor Forecast by Country (2025-2030)
10.4.1 Germany Oral TYK2 Inhibitor Market Forecast
10.4.2 France Oral TYK2 Inhibitor Market Forecast
10.4.3 UK Oral TYK2 Inhibitor Market Forecast
10.4.4 Italy Oral TYK2 Inhibitor Market Forecast
10.4.5 Russia Oral TYK2 Inhibitor Market Forecast
10.5 Middle East & Africa Oral TYK2 Inhibitor Forecast by Region (2025-2030)
10.5.1 Egypt Oral TYK2 Inhibitor Market Forecast
10.5.2 South Africa Oral TYK2 Inhibitor Market Forecast
10.5.3 Israel Oral TYK2 Inhibitor Market Forecast
10.5.4 Turkey Oral TYK2 Inhibitor Market Forecast
10.5.5 GCC Countries Oral TYK2 Inhibitor Market Forecast
10.6 Global Oral TYK2 Inhibitor Forecast by Type (2025-2030)
10.7 Global Oral TYK2 Inhibitor Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Oral TYK2 Inhibitor Product Offered
11.1.3 Bristol-Myers Squibb Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bristol-Myers Squibb Main Business Overview
11.1.5 Bristol-Myers Squibb Latest Developments
11.2 InnoCare Pharma
11.2.1 InnoCare Pharma Company Information
11.2.2 InnoCare Pharma Oral TYK2 Inhibitor Product Offered
11.2.3 InnoCare Pharma Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 InnoCare Pharma Main Business Overview
11.2.5 InnoCare Pharma Latest Developments
11.3 Takeda (Nimbus Therapeutics)
11.3.1 Takeda (Nimbus Therapeutics) Company Information
11.3.2 Takeda (Nimbus Therapeutics) Oral TYK2 Inhibitor Product Offered
11.3.3 Takeda (Nimbus Therapeutics) Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Takeda (Nimbus Therapeutics) Main Business Overview
11.3.5 Takeda (Nimbus Therapeutics) Latest Developments
11.4 E-nitiate Biopharmaceuticals
11.4.1 E-nitiate Biopharmaceuticals Company Information
11.4.2 E-nitiate Biopharmaceuticals Oral TYK2 Inhibitor Product Offered
11.4.3 E-nitiate Biopharmaceuticals Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 E-nitiate Biopharmaceuticals Main Business Overview
11.4.5 E-nitiate Biopharmaceuticals Latest Developments
11.5 Highlightll Pharmaceutical
11.5.1 Highlightll Pharmaceutical Company Information
11.5.2 Highlightll Pharmaceutical Oral TYK2 Inhibitor Product Offered
11.5.3 Highlightll Pharmaceutical Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Highlightll Pharmaceutical Main Business Overview
11.5.5 Highlightll Pharmaceutical Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Oral TYK2 Inhibitor Product Offered
11.6.3 Pfizer Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Alumis Inc.
11.7.1 Alumis Inc. Company Information
11.7.2 Alumis Inc. Oral TYK2 Inhibitor Product Offered
11.7.3 Alumis Inc. Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Alumis Inc. Main Business Overview
11.7.5 Alumis Inc. Latest Developments
11.8 Galapagos NV
11.8.1 Galapagos NV Company Information
11.8.2 Galapagos NV Oral TYK2 Inhibitor Product Offered
11.8.3 Galapagos NV Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Galapagos NV Main Business Overview
11.8.5 Galapagos NV Latest Developments
11.9 Ventyx Biosciences
11.9.1 Ventyx Biosciences Company Information
11.9.2 Ventyx Biosciences Oral TYK2 Inhibitor Product Offered
11.9.3 Ventyx Biosciences Oral TYK2 Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Ventyx Biosciences Main Business Overview
11.9.5 Ventyx Biosciences Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15 10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る